nach oben

Erschienen in:

01.02.2019 | Original Article

Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients

verfasst von: Martin-Walter Welker, Nina Weiler, Wolf Otto Bechstein, Eva Herrmann, Christoph Betz, Mark Schöffauer, Stefan Zeuzem, Christoph Sarrazin, Kerstin Amann, Oliver Jung

Erschienen in: Journal of Nephrology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

Chronic kidney disease (CKD) is a common complication after liver transplantation (LT). The etiology of CKD is broad and may only be assessed accurately by renal histology. The current study aimed to analyze the safety of renal biopsy in daily clinical practice as well as its usefulness regarding management of CKD after LT.

Methods

We performed a retrospective analysis of clinical data and renal biopsies obtained from patients with severe renal impairment (overt proteinuria, progressive deterioration of renal function) after LT with respect to safety, etiology of renal disease, and therapeutic consequences.

Results

Renal biopsies were obtained from 14 patients at median (minimum–maximum) 3 (0.2–12) years after LT. No major complications associated with renal biopsy were observed. Histomorphological alterations were varied (nephrosclerosis, n = 5; IgA-glomerulonephritis, n = 4; tenofovir-associated nephropathy, membranoproliferative glomerulonephritis type 1, membranous glomerulonephritis, amyloid A amyloidosis, and calcineurin inhibitor nephropathy, n = 1, respectively). The diagnosis of specific renal diseases other than calcineurin-inhibitor nephrotoxicity facilitated specific treaments and avoided unnecessary modification of immunosuppression in the majority of patients.

Conclusions

Renal biopsy in patients with CKD after LT seems safe and may offer specific therapeutic options. Furthermore, unnecessary changes of immunosuppression can be avoided in a considerable number of patients.

Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW et al (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349(10):931–940CrossRef

Allen AM, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD (2014) Chronic kidney disease and associated mortality after liver transplantation—a time-dependent analysis using measured glomerular filtration rate. J Hepatol 61(2):286–292CrossRefPubMedPubMedCentral

Moreno JM, Cuervas-Mons V, Rubio E, Pons F, Herreros de TA, Turrión VS et al (2003) Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transpl Proc 35(5):1907–1908CrossRef

Ziolkowski J, Paczek L, Senatorski G, Niewczas M, Oldakowska-Jedynak U, Wyzgal J et al (2003) Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transpl Proc 35(6):2307–2309CrossRef

Kim J-Y, Akalin E, Dikman S, Gagliardi R, Schiano T, Bromberg J et al (2010) The variable pathology of kidney disease after liver transplantation. Transplantation 89(2):215–221CrossRefPubMed

Giusto M, Berenguer M, Merkel C, Aguilera V, Rubin A, Ginanni Corradini S et al (2013) Chronic kidney disease after liver transplantation: pretransplantation risk factors and predictors during follow-up. Transplantation 95(9):1148–1153CrossRefPubMed

Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G et al (2011) Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transpl 11(5):965–976CrossRef

Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H et al (2009) Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the “ReSpECT” study. Am J Transpl 9(2):327–336CrossRef

TruneČka P, Klempnauer J, Bechstein WO, Pirenne J, Friman S, Zhao A et al (2015) Renal Function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens—the DIAMOND study. Am J Transpl 15(7):1843–1845CrossRef

10.

De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F et al (2012) Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transpl 12(11):3008–3020CrossRef

11.

Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al (2014) Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transpl 14(3):701–710CrossRef

12.

Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A et al (2010) Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transpl 10(10):2252–2262CrossRef

13.

Kornberg A, Küpper B, Thrum K, Krause B, Büchler P, Kornberg J et al (2011) Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction. Dig Dis Sci 56(1):244–251CrossRefPubMed

14.

Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C et al (2013) Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 19(7):675–689CrossRefPubMed

15.

Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, Malagó M et al (2007) Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients—assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 26(9):1195–1208CrossRefPubMed

16.

Créput C, Blandin F, Deroure B, Roche B, Saliba F, Charpentier B et al (2007) Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Tanspl 13(7):1004–1010CrossRef

17.

Ponton C, Vizcaíno L, Tomé S, Otero E, Molina E, Castroagudín JF et al (2010) Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction. Transpl Proc 42(2):656–659CrossRef

18.

Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z et al (2011) Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One 6(9):e24387CrossRefPubMedPubMedCentral

19.

Reich DJ, Clavien PA, Hodge EE (2005) Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 80(1):18–25CrossRefPubMed

20.

Pageaux G-P, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J et al (2006) Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Tanspl 12(12):1755–1760CrossRef

21.

Watson CJE, Gimson AES, Alexander GJ, Allison MED, Gibbs P, Smith JC et al (2007) A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Tanspl 13(12):1694–1702CrossRef

22.

De Simone P, Carrai P, Precisi A, Petruccelli S, Baldoni L, Balzano E et al (2009) Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 22(3):279–286CrossRefPubMed

23.

Gerhardt T, Terjung B, Knipper P, Palmedo H, Woitas RP, Kalff J et al (2009) Renal impairment after liver transplantation—a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res 14(5):210–215CrossRefPubMedPubMedCentral

24.

Beckebaum S, Klein CG, Sotiropoulos GC, Saner FH, Gerken G, Paul A et al (2009) Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transpl Proc 41(6):2567–2569CrossRef

25.

Herlenius G, Felldin M, Nordén G, Olausson M, Bäckman L, Gustafsson B et al (2010) Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. Transpl Proc 42(10):4441–4448CrossRef

26.

Schnitzbauer AA, Sothmann J, Baier L, Bein T, Geissler EK, Scherer MN et al (2015) Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07). Transplantation 99(12):2565–2575CrossRefPubMed

27.

Fujinaga K, Usui M, Yamamoto N, Ishikawa E, Nakatani A, Kishiwada M et al (2014) Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy. Transpl Proc 46(3):804–810CrossRef

28.

Lee JH, Cho YH, Ryu SJ, Kim SS, Lee YH, Jang I-A et al (2013) Clinical usefulness of kidney biopsy in liver transplant recipients with renal impairment. Kidney Res Clin Pr 32(4):153–157CrossRef

29.

Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y et al (2005) Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transpl 5(5):1120–1129CrossRef

30.

Pichler RH, Huskey J, Kowalewska J, Moiz A, Perkins J, Davis CL et al (2016) Kidney biopsies may help predict renal function after liver transplantation. Transplantation 100(10):2122–2128CrossRefPubMed

31.

Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L et al (2015) De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int 28(12):1371–1382CrossRefPubMed

32.

Fuiano G, Mazza G, Comi N, Caglioti A, De Nicola L, Iodice C et al (2000) Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 35(3):448–457CrossRefPubMed

33.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefPubMedPubMedCentral

34.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2012) KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int S2(5):337–341

35.

Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group (2013) KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int S3(3):259–305

36.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int S3(1):1–150

37.

Jung O, Haack HS, Buettner M, Betz C, Stephan C, Gruetzmacher P et al (2012) Renal AA-amyloidosis in intravenous drug users—a role for HIV-infection? BMC Nephrol 13:151CrossRefPubMedPubMedCentral

38.

Naesens M, Kuypers DRJ, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508CrossRef

39.

Esposito V, Mazzon G, Baiardi P, Torreggiani M, Semeraro L, Catucci D et al (2018) Safety and adequacy of percutaneous kidney biopsy performed by nephrology trainees. BMC Nephrol 19(1):14CrossRefPubMedPubMedCentral

40.

Collins BS, Davis CL, Marsh CL, McVicar JP, Perkins JD, Alpers CE (1992) Reversible cyclosporine arteriolopathy. Transplantation 54(4):732–734CrossRefPubMed

41.

Morozumi K, Thiel G, Albert FW, Banfi G, Gudat F, Mihatsch MJ (1992) Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 38(1):1–8PubMed

Titel: Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients
verfasst von: Martin-Walter Welker
Nina Weiler
Wolf Otto Bechstein
Eva Herrmann
Christoph Betz
Mark Schöffauer
Stefan Zeuzem
Christoph Sarrazin
Kerstin Amann
Oliver Jung
Publikationsdatum: 01.02.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 1/2019
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-018-0506-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Microbiota issue in CKD: how promising are gut-targeted approaches?

Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study

Subclinical AKI: ready for primetime in clinical practice?

Increased but stable isoagglutinin titers in hemodialysis patients

Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease